Trial ID or NCT#



recruiting iconRECRUITING


The primary objective of this study is to evaluate the safety and tolerability of brexucabtagene autoleucel (KTE-X19) in adults with relapsed/refractory chronic lymphocytic leukemia (r/r CLL) and small lymphocytic lymphoma (r/r SLL).

Official Title

A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of KTE-X19 in Adult Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


Steven Coutre
Steven Coutre
Hematologist, Leukemia specialist
Professor of Medicine (Hematology) at the Stanford University Medical Center

Contact us to find out if this trial is right for you.


Won W. Chang
(650) 736-8113